| Literature DB >> 29344177 |
Lili Wang1, Yan Li2, Xia Zhang3, Hongxia Li4.
Abstract
The present study was planned to investigate the characteristics of nosocomial infection and its effects on the survival in advanced non-small cell lung cancer (NSCLC) patients. Retrospective analysis was performed for the 169 chemotherapy patients with NSCLC and nosocomial infection during hospitalization in Binzhou City Central Hospital from March, 2013 to January, 2015. In addition, 170 patients without nosocomial infection were also involved as a control group. The distribution of major drug resistance of Gram-negative (G-) and Gram-positive (G+) were analyzed. The survival conditions of the patients were analyzed according to the nosocomial infection occurrence. The risk factors of nosocomial infection in patients with NSCLC were analyzed by univariate and multivariate logistic analysis. The percentage of G+ infection was 45.6% while G- infection was 54.4%. Nosocomial infections were most common in respiratory system. The median survival time of the observation group was shorter than that of the control group (P<0.05). G- infection was the most common type of infection in nosocomial infection of the patients with NSCLC. The occurrence of infection seriously affected the survival time of patients. Attention is required to the patients older than 60 years undergoing treatment with glucocorticoids as well as immunosuppressive agents.Entities:
Keywords: effects on survival; non-small cell lung cancer; nosocomial infection
Year: 2017 PMID: 29344177 PMCID: PMC5755245 DOI: 10.3892/ol.2017.7144
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
The distribution of pathogens in nosocomial infection in chemotherapy patients with advanced NSCLC.
| Pathogen species | No. of strains (n) | Proportion (%) |
|---|---|---|
| G+ | 45.6 | |
| 41 | 24.3 | |
| Coagulase-negative | 36 | 21.3 |
| G− | 54.4 | |
| 27 | 16.0 | |
| 23 | 13.6 | |
| 19 | 11.2 | |
| 14 | 8.3 | |
| 9 | 5.3 |
G+, Gram-positive; G−, Gram-negative; NSCLC, non-small cell lung cancer.
The main drug resistance distribution of G− [n (%)].
| Antibiotics | ||
|---|---|---|
| Cefotaxime | 13 (48.1) | 5 (21.7) |
| Cefepime | 9 (33.3) | 6 (26.1) |
| Ceftazidime | 9 (33.3) | 6 (26.1) |
| Amikacin | 6 (22.2) | 4 (17.4) |
| Ciprofloxacin | 15 (55.6) | 5 (21.7) |
| Levofloxacin | 7 (25.9) | 6 (26.1) |
| Imipenem | 7 (25.9) | 0 (0) |
| Meropenem | 6 (22.2) | 0 (0) |
| Sulfamethoxazole | 16 (59.3) | 11 (47.8) |
| Gentamicin | 12 (44.4) | 9 (39.1) |
G−, Gram-negative.
The main drug resistance distribution of G+ [n (%)].
| Antibiotics | Coagulase-negative staphylococci (n=36) | |
|---|---|---|
| Penicillin G | 40 (97.6) | 35 (97.2) |
| Ampicillin | 39 (95.1) | 34 (94.4) |
| Erythromycin | 18 (43.9) | 11 (30.6) |
| Roxithromycin | 19 (46.3) | 9 (25.0) |
| Vancomycin | 0 (0) | 0 (0) |
| Teicoplanin | 0 (0) | 0 (0) |
| Sulfamethoxazole | 23 (56.1) | 20 (55.6) |
| Gentamicin | 12 (29.3) | 11 (30.6) |
| Ciprofloxacin | 11 (26.8) | 16 (44.4) |
| Levofloxacin | 17 (41.5) | 13 (36.1) |
G+, Gram-positive.
The characteristics of distribution of nosocomial infection sites.
| Infection sites | Infection cases (case) | Infection rate (%) |
|---|---|---|
| Respiratory system | 102 | 60.4 |
| Digestive system | 35 | 20.7 |
| Urinary system | 51 | 30.2 |
| Blood system | 21 | 12.4 |
| Skin and soft tissue | 10 | 5.9 |
| Other parts | 3 | 1.8 |
Figure 1.The characteristics of distribution of nosocomial infection sites.
Analysis of risk factors of nosocomial infection in patients with advanced NSCLC.
| Risk factors | Cases | Infection rate (%) |
|---|---|---|
| Sex | ||
| Male | 125 | 74.0 |
| Female | 44 | 26.0 |
| Age (years) | ||
| ≥60 | 100 | 59.2 |
| <60 | 69 | 40.8 |
| Length of hospitalization | ||
| ≥30 days | 95 | 65.1 |
| <30 days | 74 | 34.9 |
| Invasive operation | ||
| Yes | 115 | 68.0 |
| No | 54 | 32.0 |
| Combination of two or more medical diseases | ||
| Yes | 100 | 59.2 |
| No | 69 | 40.8 |
| Preventive use of antimicrobial agents | ||
| Yes | 75 | 44.4 |
| No | 94 | 55.6 |
| Use of glucocorticoids | ||
| Yes | 123 | 72.8 |
| No | 46 | 27.2 |
| Use of immunosuppressive agents | ||
| Yes | 111 | 65.7 |
| No | 58 | 34.3 |
NSCLC, non-small cell lung cancer.
Multivariate logistic analysis of nosocomial infection in patients with advanced NSCLC.
| Independent risk factors | Partial regression coefficient | Standard error | P-value | OR value | χ2 value |
|---|---|---|---|---|---|
| Age over 60 years | 0.321 | 0.203 | 0.012 | 1.025 | 6.361 |
| Invasive operation | 0.565 | 0.256 | 0.002 | 0.785 | 10.253 |
| Combination of two or more medical diseases | 0.296 | 0.134 | 0.032 | 1.323 | 4.377 |
| Preventive use of antimicrobial agents | −0.326 | 0.135 | 0.004 | 0.811 | 6.581 |
| Use of glucocorticoids | 0.409 | 0.158 | 0.003 | 0.623 | 8.956 |
| Use of immunosuppressive agents | 0.713 | 0.135 | <0.05 | 2.305 | 21.309 |
NSCLC, non-small cell lung cancer.